Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations.

Abstract:

OBJECTIVE:To identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in SAARC (South Asian Association for Regional Cooperation) nations. METHODS:Studies published in English language between 1990 and 2015 were retrieved from Medline databases using relevant search strategies. Studies were independently reviewed as per Cochrane methodology and information on the type of research and outcomes were extracted. Quality of reporting was assessed. RESULTS:Of the 2638 studies screened from eight SAARC nations, a total of 179 were included for review (India = 140; Bangladesh = 12; Sri Lanka = 8; Pakistan = 7; Afghanistan = 5; Nepal = 4; Bhutan = 2; Maldives = 1). The broad study categories were cost-effectiveness analyses (CEAs = 76 studies), cost analyses (35 studies), and burden of illness (BOI=26 studies). The outcomes evaluated were direct costs, indirect costs, and incremental cost-effectiveness ratio (ICER), quality-adjusted life-years (QALYs), and disability-adjusted life-years (DALYs). Cost of medicines, consultation and hospital charges, and monitoring costs were assessed as direct medical costs along with non-direct medical costs such as travel and food for patients and caregivers. The components of indirect costs were loss of income of patients and caregivers and loss of productivity. Quality of life (QoL) was assessed in 48 studies. The most commonly used instrument for assessing QoL was the WHO-Quality of Life BREF (WHOQOL-BREF) questionnaire (76%). The Quality of Health Economic Studies (QHES) score was used for quality assessment of full economic studies (44 studies). The mean QHES score was 43.76. CONCLUSION:This review identifies various patterns of health economic studies in eight SAARC nations. The quality of economic evaluation studies for health care in India, Bangladesh, Sri Lanka, Pakistan, Afghanistan, Nepal, Bhutan, and Maldives needs improvement. There is a need to generate the capacity of researchers to undertake quality economic evaluations as well as an orientation of the policy makers so that there is a demand for such studies as well as a scope for its use in policy making.

journal_name

Ther Innov Regul Sci

authors

Mehta M,Nerurkar R

doi

10.1177/2168479017731583

subject

Has Abstract

pub_date

2018-05-01 00:00:00

pages

348-353

issue

3

eissn

2168-4790

issn

2168-4804

journal_volume

52

pub_type

杂志文章,评审
  • Community Opinions on the Collection and Use of Historical Control Data in Nonclinical Toxicity Studies.

    abstract:BACKGROUND:Access and use of historical control data was identified as a top stakeholder concern across organizations according to results of a survey of needs and challenges related to nonclinical data conducted by the FDA/PhUSE Nonclinical Working Group in 2011. There is a perception there may be additional ways to c...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015600203

    authors: Mihalcik LM,Bausman M,Brown P,Everds N,Feldmann J,Henck J,Potenta D,Sims J,Zandee J

    更新日期:2016-03-01 00:00:00

  • Bowel Preparations for Colonoscopy: A Regulatory Perspective.

    abstract::Agents indicated for cleansing of the colon as a preparation for colonoscopy (bowel preps) are among the most frequently prescribed drugs for otherwise healthy patients. Better bowel preparation has been shown to translate into higher adenoma detection rates. Therefore, safety and efficacy standards need to be high. C...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015577868

    authors: Gottlieb K,Turner JR,Gillespie BS,Hussain F

    更新日期:2015-09-01 00:00:00

  • Assessing the Quality of Database Search Strategies Utilized by Meta-analyses That Evaluate Infectious Disease Drug Therapy.

    abstract::Meta-analyses are increasingly influencing clinical practice, but significant methodological flaws have been reported. The purpose of this study was to evaluate the quality of search strategies utilized by anti-infective meta-analyses. The Embase database was searched for meta-analyses evaluating anti-infective drug t...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013516774

    authors: Marler JL,Curry KY,Suda KJ

    更新日期:2014-05-01 00:00:00

  • Improving Drug Development and Patient Access With the Right People, Processes, and Culture: What Needs to Happen Right Now to Bring Better Medicines to the Patients Who Need Them.

    abstract::In a global environment where health care costs are soaring, R&D efforts are flatlining. Meanwhile, payers are demanding more value for their money. In this environment, the traditional siloed drug development model is not sustainable. Yet innovations such as adaptive trial designs, real-world data collection, precisi...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018814224

    authors: Grignolo A,Siu A

    更新日期:2019-05-01 00:00:00

  • A Practical Estimation Method for Analyzing Adverse Drug Reactions Using Data Mining.

    abstract::This study aimed to determine the potentially severe chemical properties of drugs that can cause adverse drug reactions (ADRs) such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) by using a data mining method. The study data were extracted from the Adverse Event Repor...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/0092861512460759

    authors: Shirakuni Y,Okamoto K,Uejima E,Inui S,Takahara JI,Ohgaru T,Yamasaki H,Tian Y,Kawashita N,Inoue R,Yasunaga T,Takagi T

    更新日期:2013-03-01 00:00:00

  • Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation.

    abstract::After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014. Althoug...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015618697

    authors: Schulthess D,Baird LG,Trusheim M,Unger TF,Lumpkin M,Hoos A,Garner S,Gavin P,Goldman M,Seigneuret N,Chlebus M,Van Baelen K,Bergstrom R,Hirsch G

    更新日期:2016-05-01 00:00:00

  • A Novel Collaborative Approach to Building Better Clinical Trials: New Insights From a Patient Engagement Workshop to Propel Patient-Centricity Forward.

    abstract:BACKGROUND:(1) A growing number of pharmaceutical and biotechnology organizations are engaging patients, their support networks, and clinical trial site staff at various touchpoints along the clinical research development spectrum to solicit feedback on how to reduce the burden of clinical trial participation and admin...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479019849875

    authors: Gregg A,Getz N,Benger J,Anderson A

    更新日期:2019-05-22 00:00:00

  • Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions.

    abstract:BACKGROUND:Increasing generic drug price competition by facilitating abbreviated new drug applications (ANDA) submission may help patients have access to affordable care. This study examined factors associated with first ANDA submission for the brand drug to be copied [the "reference listed drug" (RLD)]. METHODS:This ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00163-x

    authors: Wittayanukorn S,Rosenberg M,Schick A,Hu M,Wang Z,Babiskin A,Lionberger R,Zhao L

    更新日期:2020-11-01 00:00:00

  • Baseline Assessment of the Evolving 2017 eClinical Landscape.

    abstract::The volume and diversity of data collected to support each clinical study has increased dramatically in response to the rising scope and complexity of global drug development programs. The Tufts Center for the Study of Drug Development conducted an online survey of 257 unique global companies-77% drug development spon...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018769292

    authors: Wilkinson M,Young R,Harper B,Machion B,Getz K

    更新日期:2019-01-01 00:00:00

  • Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.

    abstract::In the current pharmaceutical regulatory environment, patients continue to benefit from great advances in medical care. Sophisticated regulatory review systems have also evolved to ensure that safe and effective medicines are approved. However, these systems are not optimized in all countries. Gaps in individual regul...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-019-00055-9

    authors: O'Brien J,Lumsden RS,Diehl DH,Macdonald JC

    更新日期:2020-03-01 00:00:00

  • Validation of QT Interval Correction Methods When a Drug Changes Heart Rate.

    abstract::The QT interval is correlated with heart rate; therefore, the QT interval is usually corrected by heart rate when drug-induced QT effect is studied. Currently, there are many correction methods that use either fixed or data-driven approaches. The effectiveness of correction methods depends on many factors and varies f...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479012467018

    authors: Dang Q,Zhang J

    更新日期:2013-03-01 00:00:00

  • Monitoring and Evaluating the Effect of Regulatory Action: Some Recent Case Studies.

    abstract::Large electronic health care databases can be used to evaluate the effectiveness of regulatory action. Designing and interpreting such studies can be challenging. We demonstrate using case studies on modafinil, benzodiazepines, dosulepin, and piroxicam that measuring the impact of regulatory action is possible and can...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015570333

    authors: Thomson A,Meeraus WH,Wong J,Suvarna R

    更新日期:2015-07-01 00:00:00

  • Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.

    abstract:BACKGROUND:Safety data are continuously evaluated throughout the life cycle of a medical product to accurately assess and characterize the risks associated with the product. The knowledge about a medical product's safety profile continually evolves as safety data accumulate. METHODS:This paper discusses data sources a...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1177/2168479017741112

    authors: Izem R,Sanchez-Kam M,Ma H,Zink R,Zhao Y

    更新日期:2018-03-01 00:00:00

  • Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.

    abstract::The regulatory agencies all over the world have defined the pathway and regulations for the approval of simple small-molecule generics. In addition, the agencies are striving to form perspicuous regulatory frameworks for the approval of biosimilars. In this view, there are no defined regulations for the approval of co...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1007/s43441-020-00114-6

    authors: Lunawat S,Bhat K

    更新日期:2020-09-01 00:00:00

  • Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area.

    abstract:BACKGROUND:A new incentive program, "Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc," was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015600205

    authors: Shibata S,Uemura R,Suzuki T

    更新日期:2016-01-01 00:00:00

  • Strategic Shift of Statistical Review on Data Quality Assessment for New Drug Applications in China.

    abstract::Data quality is critical for clinical trials to obtain robust conclusions about drug safety and efficacy evaluation. Effective data quality evaluation has been one of the major obstacles to new drug approvals in China, which hinders innovation in drug discovery and development ultimately. To improve the data quality s...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018778528

    authors: Wang J,Wang G,Li M,Han J,Zeng X,Pan J,Yang J

    更新日期:2019-03-01 00:00:00

  • An Assessment of Concerns Regarding New Regulatory Guidance for Combination Products: A Review of the Submissions Made to the FDA Regarding Their Proposed Draft New Guidance on Human Factors Studies for a Combination Product in an Abbreviated New Drug App

    abstract:BACKGROUND:The US Food and Drug Administration (FDA) put out a call for comments on new draft guidance for industry "Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA." This call for comments elicited 7 submissions from various organization...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1177/2168479018775659

    authors: Lance PT,Greenaway RV,Edwards B

    更新日期:2019-03-01 00:00:00

  • Single-Study Approvals: Quantum of Evidence Required.

    abstract::When does a single positive adequate and well-controlled study of a new drug meet the statutory requirement to demonstrate substantial evidence of effectiveness? The answer to this question, particularly with respect to new molecular entities, has been of considerable debate since 1962 when the requirement that new dr...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-019-00103-4

    authors: Sasinowski FJ,Butler ML

    更新日期:2020-05-01 00:00:00

  • Implementing the Principle of the 3 Rs Through the Indian Pharmacopoeia.

    abstract::Quality and safety tests are required for regulatory approval of drugs and pharmaceuticals in the country to guarantee minimum safety standards, and most of these tests include animal usage. In the case of biological medicines, these safety and quality tests have to be performed on a batch-to-batch basis and require a...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015572371

    authors: Rastogi S,Kalaivani M,Bhatia AK,Prakash J,Singh GN

    更新日期:2015-09-01 00:00:00

  • Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals.

    abstract:BACKGROUND:Several articles showed that statistical efficiency of multi-arm randomized clinical trials (RCTs) is much better than conventional two-arm RCTs. Multi-arm RCTs attract interest mainly when the experimental treatment regimen is not optimized or several pipelines under development exist. Breast cancer is a po...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00141-3

    authors: Nomura S,Miyauchi Y,Ajisawa Y,Isogaya K,Sozu T

    更新日期:2020-09-01 00:00:00

  • Characteristics of Drug Intervention Clinical Trials and Scientific Impact of the Trial Outcome: A Bibliometric Analysis Using the Relative Citation Ratio in Non-small Cell Lung Cancer from 2007 to 2016.

    abstract:BACKGROUND:Although a large number of clinical trials have been conducted, the types of clinical trials that are scientifically influential, frequently utilized by society, and contribute to the progress of evidence-based medicine (EBM) have not been studied. Thus, we aimed to investigate the relationship between the c...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00177-5

    authors: Noguchi Y,Kaneko M,Narukawa M

    更新日期:2020-11-01 00:00:00

  • Interdisciplinary Safety Evaluation and Quantitative Safety Monitoring: Introduction to a Series of Papers.

    abstract::The American Statistical Association and DIA have created an interdisciplinary working group of drug safety experts from academia, industry and regulatory backgrounds to explore the future direction for safety monitoring. This introduction to the series explains the background and rationale for this special section. ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018793130

    authors: Seltzer JH,Li J,Wang W

    更新日期:2019-03-29 00:00:00

  • Risk-Based Monitoring (RBM) Implementation: Challenges and Potential Solutions.

    abstract::Risk-based monitoring (RBM) has disrupted the clinical trial industry, challenging conventional monitoring norms, business processes, and organizational structures. Endorsed by regulators and leading industry forums, and further driven by escalating drug development costs and enabling technology shifts making data ava...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018769284

    authors: Limaye N,Jaguste V

    更新日期:2019-03-01 00:00:00

  • Regulatory Issues of Voluntary Certification of Food Supplements in Russia.

    abstract::When registering food supplements in Russia, restrictions on the labeling and consumer leaflet contents are tightly controlled by the regulatory agencies. Thus, misleading advertising is the most difficult problem with the turnover of these products if information in the commercials does not correspond to the informat...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1007/s43441-019-00043-z

    authors: Lozda R

    更新日期:2020-01-01 00:00:00

  • Rheumatoid Arthritis Disease Progression Modeling.

    abstract::Time progression models provide a significant advantage in developing clinical trials and can also be used to elicit comparisons among therapeutic agents. The authors performed a meta-analysis to construct a time progression model for rheumatoid arthritis (RA), an area of significant interest for pharmaceutical develo...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013499571

    authors: Reeve R,Pang L,Ferguson B,O'Kelly M,Berry S,Xiao W

    更新日期:2013-11-01 00:00:00

  • Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.

    abstract::Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval a...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015578154

    authors: Klopfenstein M,Van Campen LE,Garnett T

    更新日期:2015-05-01 00:00:00

  • Product Registration in Developing Countries: A Proposal for an Integrated Regional Licensing System Among Countries in Regional Economic Blocs.

    abstract::The product pipeline for diseases that disproportionately affect the developing world has considerably expanded over the last decade. Indeed, there are about 134 products for these diseases in the pipeline, including vaccines, drugs, diagnostics, microbicides, and vector control tools, and dozens of these products are...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013478952

    authors: Saidu Y,De Angelis D,Aiolli S,Stefano G,Georges AM

    更新日期:2013-05-01 00:00:00

  • How FDA Advisory Committee Members Prepare and What Influences Them.

    abstract::Since 1992 many changes have occurred in the regulations, guidelines, and processes governing the FDA, the biomedical industry, other stakeholders, and their interactions. Of particular importance, the FDA Amendments Act of 2007 made public advisory committee meetings mandatory for new molecular entities and devices r...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/0092861512458096

    authors: McIntyre TD,Pappas M,DiBiasi JJ

    更新日期:2013-01-01 00:00:00

  • Adaptive Design: Results of 2012 Survey on Perception and Use.

    abstract::Adaptive designs are increasingly used in clinical trials. The Drug Information Association's Adaptive Design Scientific Working Group (ADSWG) works to foster collaboration among regulatory agencies, academia, and pharmaceutical and biotech companies to further the science of adaptive clinical development. The ADSWG S...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014522468

    authors: Morgan CC,Huyck S,Jenkins M,Chen L,Bedding A,Coffey CS,Gaydos B,Wathen JK

    更新日期:2014-07-01 00:00:00

  • A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?

    abstract::A universal framework for the evaluation of the benefit-risk assessment of medicines during development by pharmaceutical companies and in the regulatory review by regulatory authorities is considered of value, as it would result in the systematic structured approach to support transparency in decision making. Several...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014547421

    authors: Walker S,McAuslane N,Liberti L,Leong J,Salek S

    更新日期:2015-01-01 00:00:00